{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:28:20Z","timestamp":1747643300035,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PUE 2018-0042","PIP 2021-1779"],"award-info":[{"award-number":["PUE 2018-0042","PIP 2021-1779"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-05794-w","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T04:17:00Z","timestamp":1715660220000},"page":"5703-5712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants"],"prefix":"10.1007","volume":"103","author":[{"given":"Mar\u00eda Bel\u00e9n","family":"Fontecha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Del Rosario","family":"Anad\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Mercado Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Stanganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Galvano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Tosin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimundo","family":"Bezares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Slavutsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4000-0519","authenticated-orcid":false,"given":"Ariela Freya","family":"Fundia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"5794_CR1","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ et al (2017) Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3:16096. https:\/\/doi.org\/10.1038\/nrdp.2016.96","journal-title":"Nat Rev Dis Primers"},{"key":"5794_CR2","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"J Delgado","year":"2020","unstructured":"Delgado J, Nadeu F, Colomer D, Campo E (2020) Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica 105:2205\u20132217. https:\/\/doi.org\/10.3324\/haematol.2019.236000","journal-title":"Haematologica"},{"key":"5794_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bjh.13933","volume":"173","author":"DL Van Dyke","year":"2016","unstructured":"Van Dyke DL, Werner L, Rassenti LZ et al (2016) The D\u00f6hner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol 173:105\u2013113. https:\/\/doi.org\/10.1111\/bjh.13933","journal-title":"Br J Haematol"},{"key":"5794_CR4","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","volume":"103","author":"E Campo","year":"2018","unstructured":"Campo E, Cymbalista F, Ghia P et al (2018) TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica 103:1956\u20131968. https:\/\/doi.org\/10.3324\/haematol.2018.187583","journal-title":"Haematologica"},{"key":"5794_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2018.195032","volume":"104","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Moysiadis T, Hadzidimitriou A et al (2019) Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica 104:360\u2013369. https:\/\/doi.org\/10.3324\/haematol.2018.195032","journal-title":"Haematologica"},{"key":"5794_CR6","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B (2018) Chronic lymphocytic leukaemia. Lancet 391:1524\u20131537. https:\/\/doi.org\/10.1016\/S0140-6736(18)30422-7","journal-title":"Lancet"},{"key":"5794_CR7","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41418-022-00999-w","volume":"29","author":"MS Lindstr\u00f6m","year":"2022","unstructured":"Lindstr\u00f6m MS, Bartek J, Maya-Mendoza A (2022) p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways. Cell Death Differ 29:972\u2013982. https:\/\/doi.org\/10.1038\/s41418-022-00999-w","journal-title":"Cell Death Differ"},{"key":"5794_CR8","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.3390\/cancers14235733","volume":"14","author":"A Amendolare","year":"2022","unstructured":"Amendolare A, Marzano F, Petruzzella V et al (2022) The underestimated role of the p53 pathway in renal cancer. Cancers (Basel) 14:5733. https:\/\/doi.org\/10.3390\/cancers14235733","journal-title":"Cancers (Basel)"},{"key":"5794_CR9","doi-asserted-by":"publisher","unstructured":"Lod\u00e9 L, Cymbalista F, Soussi T (2016) Genetic profiling of CLL: a \u2018TP53 addict\u2019 perspective. Cell Death Dis 7: e2042. https:\/\/doi.org\/10.1038\/cddis.2015.415","DOI":"10.1038\/cddis.2015.415"},{"key":"5794_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.21037\/tcr.2016.11.75","volume":"5","author":"MI Carr","year":"2016","unstructured":"Carr MI, Jones SN (2016) Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Transl Cancer Res 5:707\u2013724. https:\/\/doi.org\/10.21037\/tcr.2016.11.75","journal-title":"Transl Cancer Res"},{"key":"5794_CR11","doi-asserted-by":"publisher","unstructured":"Asher G, Lotem J, Cohen B, Sachs L, Shaul (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Nat Acad Sci U S A 98:1188\u20131193. https:\/\/doi.org\/10.1073\/pnas.98.3.1188","DOI":"10.1073\/pnas.98.3.1188"},{"key":"5794_CR12","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1158\/0008-5472.CAN-20-0177","volume":"81","author":"P Zhang","year":"2021","unstructured":"Zhang P, Kitchen-Smith I, Xiong L et al (2021) Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response. Cancer Res 81:1667\u20131680. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0177","journal-title":"Cancer Res"},{"key":"5794_CR13","doi-asserted-by":"publisher","first-page":"808886","DOI":"10.3389\/fonc.2022.808886","volume":"12","author":"T Soussi","year":"2022","unstructured":"Soussi T, Baliakas P (2022) Landscape of TP53 alterations in chronic lymphocytic leukemia via Data Mining Mutation databases. Front Oncol 12:808886. https:\/\/doi.org\/10.3389\/fonc.2022.808886","journal-title":"Front Oncol"},{"key":"5794_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/hon.3063","volume":"40","author":"G De Luca","year":"2022","unstructured":"De Luca G, Cerruti G, Lastraioli S et al (2022) The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: a next generation sequencing retrospective study. Hematol Oncol 40:962\u2013975. https:\/\/doi.org\/10.1002\/hon.3063","journal-title":"Hematol Oncol"},{"key":"5794_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/13543784.2020.1783239","volume":"29","author":"F Morabito","year":"2020","unstructured":"Morabito F, Gentile M, Monti P et al (2020) TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. Expert Opin Investig Drugs 29:869\u2013880. https:\/\/doi.org\/10.1080\/13543784.2020.1783239","journal-title":"Expert Opin Investig Drugs"},{"key":"5794_CR16","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O (2021) Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol 96:1679\u20131705. https:\/\/doi.org\/10.1002\/ajh.26367","journal-title":"Am J Hematol"},{"key":"5794_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.18502\/ijhoscr.v15i3.6846","volume":"15","author":"N Jalilian","year":"2021","unstructured":"Jalilian N, Maleki Y, Shakiba E et al (2021) p53 p.Pro72Arg (rs1042522) and mouse double minute 2 (MDM2) single-nucleotide polymorphism (SNP) 309 variants and their interaction in chronic lymphocytic leukemia(CLL): A survey in CLL patients from Western Iran. Int J Hematol-Oncol Stem Cell Res 15:160\u2013169. https:\/\/doi.org\/10.18502\/ijhoscr.v15i3.6846","journal-title":"Int J Hematol-Oncol Stem Cell Res"},{"key":"5794_CR18","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"5794_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/mutage\/gez009","volume":"34","author":"M Palmitelli","year":"2019","unstructured":"Palmitelli M, Stanganelli C, Stella F et al (2019) Analysis of basal chromosome instability in patients with chronic lymphocytic leukemia. Mutagenesis 34:245\u2013252. https:\/\/doi.org\/10.1093\/mutage\/gez009","journal-title":"Mutagenesis"},{"key":"5794_CR20","doi-asserted-by":"publisher","unstructured":"McGowan-Jordan J, Hastings RJ, Moore S (eds) (2020) ISCN. An International System for Human Cytogenomic Nomenclature. Cytogenet Genome Res 160:341\u2013503. https:\/\/doi.org\/10.1159\/000516655","DOI":"10.1159\/000516655"},{"key":"5794_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.clml.2013.02.019","volume":"13","author":"C Stanganelli","year":"2013","unstructured":"Stanganelli C, Travella A, Bezares R, Slavutsky I (2013) Immunoglobulin gene rearrangements and mutational status in Argentinian patients with chronic lymphocytic leukemia. Clin Lymph Myeloma Leuk 13:447\u2013457. https:\/\/doi.org\/10.1016\/j.clml.2013.02.019","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"5794_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","volume":"32","author":"J Malcikova","year":"2018","unstructured":"Malcikova J, Tausch E, Rossi D et al (2018) ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia 32:1070\u20131080. https:\/\/doi.org\/10.1038\/s41375-017-0007-7","journal-title":"Leukemia"},{"key":"5794_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.gene.2012.05.024","volume":"504","author":"B Lajin","year":"2012","unstructured":"Lajin B, Alachkar A, Alhaj Sakur A (2012) A quadruplex tetra-primer ARMS\u2013PCR method for the simultaneous detection of TP53 Arg72Pro, IVS3 16\u00a0bp Del\/Ins and IVS6\u2009+\u200962A\u2009>\u2009G, and NQO1 C609T polymorphisms. Gene 504:268\u2013273. https:\/\/doi.org\/10.1016\/j.gene.2012.05.024","journal-title":"Gene"},{"key":"5794_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.gene.2012.01.004","volume":"497","author":"D Dong","year":"2012","unstructured":"Dong D, Gao X, Zhu Z, Yu Q, Bian S, Gao Y (2012) A 40-bp insertion\/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population. Gene 497:66\u201370. https:\/\/doi.org\/10.1016\/j.gene.2012.01.004","journal-title":"Gene"},{"key":"5794_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/humu.20277","volume":"27","author":"X Zhang","year":"2006","unstructured":"Zhang X, Miao X, Guo Y et al (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27:110\u2013117. https:\/\/doi.org\/10.1002\/humu.20277","journal-title":"Hum Mutat"},{"key":"5794_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263\u2013265. https:\/\/doi.org\/10.1093\/bioinformatics\/bth457","journal-title":"Bioinformatics"},{"key":"5794_CR27","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1007\/s00277-018-3503-6","volume":"97","author":"V Buccheri","year":"2018","unstructured":"Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V (2018) Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Ann Hematol 97:2269\u20132278. https:\/\/doi.org\/10.1007\/s00277-018-3503-6","journal-title":"Ann Hematol"},{"key":"5794_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.leukres.2005.12.014","volume":"30","author":"G Kochethu","year":"2006","unstructured":"Kochethu G, Delgado J, Pepper C et al (2006) Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 30:1113\u20131118. https:\/\/doi.org\/10.1016\/j.leukres.2005.12.014","journal-title":"Leuk Res"},{"key":"5794_CR29","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.31557\/APJCP.2019.20.5.1579","volume":"20","author":"AA Mohammed Basabaeen","year":"2019","unstructured":"Mohammed Basabaeen AA, Abdelgader EA, Babekir EA et al (2019) TP53 gene 72 Arg\/Pro (rs1042522) single nucleotide polymorphism contribute to increase the risk of B-Chronic lymphocytic leukemia in the Sudanese Population. Asian Pac J Cancer Prev 20:1579\u20131585. https:\/\/doi.org\/10.31557\/APJCP.2019.20.5.1579","journal-title":"Asian Pac J Cancer Prev"},{"key":"5794_CR30","doi-asserted-by":"publisher","first-page":"1272876","DOI":"10.3389\/fonc.2023.1272876","volume":"13","author":"A Ounalli","year":"2023","unstructured":"Ounalli A, Moumni I, Mechaal A, Chakroun A, Barmat M, Rhim REE, Menif S, Safra I (2023) TP53 gene 72 Arg\/Pro (rs1042522) single nucleotide polymorphism increases the risk and the severity of chronic lymphocytic leukemia. Front Oncol 13:1272876. https:\/\/doi.org\/10.3389\/fonc.2023.1272876","journal-title":"Front Oncol"},{"key":"5794_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2017.03.009","volume":"58","author":"N Bilous","year":"2017","unstructured":"Bilous N, Abramenko I, Saenko V et al (2017) Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia. Leuk Res 58:1\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2017.03.009","journal-title":"Leuk Res"},{"key":"5794_CR32","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/ijc.26222","volume":"130","author":"HJ Dong","year":"2012","unstructured":"Dong HJ, Fang C, Fan L et al (2012) MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer 130:2054\u20132061. https:\/\/doi.org\/10.1002\/ijc.26222","journal-title":"Int J Cancer"},{"key":"5794_CR33","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3109\/10428194.2012.691485","volume":"53","author":"W Zhuo","year":"2012","unstructured":"Zhuo W, Zhang L, Ling J, Zhu B, Chen Z (2012) MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects. Leuk Lymph 53:2245\u20132252. https:\/\/doi.org\/10.3109\/10428194.2012.691485","journal-title":"Leuk Lymph"},{"key":"5794_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.leukres.2008.06.030","volume":"33","author":"A Begleiter","year":"2009","unstructured":"Begleiter A, Hewitt D, Gibson SB, Johnston JB (2009) Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia. Leuk Res 33:74\u201381. https:\/\/doi.org\/10.1016\/j.leukres.2008.06.030","journal-title":"Leuk Res"},{"key":"5794_CR35","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.3892\/ol.2019.10048","volume":"17","author":"Y Maleki","year":"2019","unstructured":"Maleki Y, Alahbakhshi Z, Heidari Z et al (2019) NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia. Oncol Lett 17:4016\u20134023. https:\/\/doi.org\/10.3892\/ol.2019.10048","journal-title":"Oncol Lett"},{"key":"5794_CR36","doi-asserted-by":"publisher","first-page":"a026302","DOI":"10.1101\/cshperspect.a026302","volume":"6","author":"S Basu","year":"2016","unstructured":"Basu S, Murphy ME (2016) Genetic modifiers of the p53 pathway. Cold Spring Harb Perspect Med 6:a026302. https:\/\/doi.org\/10.1101\/cshperspect.a026302","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5794_CR37","first-page":"223","volume":"19","author":"NI Bilous","year":"2014","unstructured":"Bilous NI, Abramenko IV, Chumak AA, Dyagil IS, Martina ZV (2014) Gene polymorphisms of p53-mediated apoptosis in chronic lymphocytic leukemia patients: features of distribution depending on radiation factor in anamnesis. Probl Rad Med Radiobiol 19:223\u2013230","journal-title":"Probl Rad Med Radiobiol"},{"key":"5794_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/10428194.2016.1211276","volume":"58","author":"K Gemenetzi","year":"2017","unstructured":"Gemenetzi K, Galigalidou C, Vlachonikola E et al (2017) Tp53 gene p72R polymorphism in chronic lymphocytic leukemia: incidence and clinical significance amongst cases with unmutated immunoglobulin receptors. Leuk Lymph 58:726\u2013728. https:\/\/doi.org\/10.1080\/10428194.2016.1211276","journal-title":"Leuk Lymph"},{"key":"5794_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1365-2141.2010.08484.x","volume":"153","author":"A Majid","year":"2011","unstructured":"Majid A, Richards T, Dusanjh P et al (2011) TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol 153:533\u2013535. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08484.x","journal-title":"Br J Haematol"},{"key":"5794_CR40","doi-asserted-by":"publisher","unstructured":"Cabrero-Becerra MA, Garc\u00eda-Vela J, S\u00e1nchez-Godoy P, Arias-Arias A, Garc\u00eda-Marcos JA (2021) Influence of polymorphisms of codon 72 of tp53 in patients with chronic lymphocytic leukemia. in HemaSphere. 5(S2): pp 276\u2013277. Abstract book. https:\/\/doi.org\/10.1097\/HS9.0000000000000566","DOI":"10.1097\/HS9.0000000000000566"},{"key":"5794_CR41","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/dna.1995.14.983","volume":"14","author":"S Peller","year":"1995","unstructured":"Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K, Rotter V (1995) A Novel Polymorphism in Intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 14:983\u2013990. https:\/\/doi.org\/10.1089\/dna.1995.14.983","journal-title":"DNA Cell Biol"},{"key":"5794_CR42","first-page":"98","volume":"21","author":"C Sauka","year":"2008","unstructured":"Sauka C, Koh\u00fat A, Kundr\u00e1t I, Jan\u00edk M (2008) Polymorfizmus g\u00e9nu p 53 a apopt\u00f3za u pacientov s n\u00e1dormi pl\u2019\u00fac\u2013nase sledovanie [Polymorphism of gene p53 and apoptosis in patients with malignant lung disease\u2013our observation]. Klin Onkol 21:98\u2013103","journal-title":"Klin Onkol"},{"key":"5794_CR43","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/jnci\/94.9.681","volume":"94","author":"X Wu","year":"2002","unstructured":"Wu X, Zhao H, Amos CI et al (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Nat Cancer Inst 94:681\u2013690. https:\/\/doi.org\/10.1093\/jnci\/94.9.681","journal-title":"J Nat Cancer Inst"},{"key":"5794_CR44","first-page":"1495","volume":"46","author":"GF Mukhammadiyeva","year":"2017","unstructured":"Mukhammadiyeva GF, Karimov DO, Bakirov AB, Karimova LK (2017) TP53 gene polymorphisms and occupational skin Cancer risks for workers of glass Fiber manufacture. Iran J Publ Health 46:1495\u20131501","journal-title":"Iran J Publ Health"},{"key":"5794_CR45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","volume":"119","author":"GL Bond","year":"2004","unstructured":"Bond GL, Hu W, Bond EE et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591\u2013602. https:\/\/doi.org\/10.1016\/j.cell.2004.11.022","journal-title":"Cell"},{"key":"5794_CR46","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/sj.onc.1210199","volume":"26","author":"GL Bond","year":"2007","unstructured":"Bond GL, Levine AJ (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 26:1317\u20131323. https:\/\/doi.org\/10.1038\/sj.onc.1210199","journal-title":"Oncogene"},{"key":"5794_CR47","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1200\/JCO.2007.11.5212","volume":"26","author":"I Gryshchenko","year":"2008","unstructured":"Gryshchenko I, Hofbauer S, Stoecher M et al (2008) MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 26:2252\u20132257. https:\/\/doi.org\/10.1200\/JCO.2007.11.5212","journal-title":"J Clin Oncol"},{"key":"5794_CR48","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1600-0609.2010.01470.x","volume":"85","author":"K Willander","year":"2010","unstructured":"Willander K, Ungerb\u00e4ck J, Karlsson K, Fredrikson M, S\u00f6derkvist P, Linderholm M (2010) MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Eur J Haematol 85:251\u2013256. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01470.x","journal-title":"Eur J Haematol"},{"key":"5794_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1471-2407-5-105","volume":"5","author":"I Sturm","year":"2005","unstructured":"Sturm I, Bosanquet AG, Hummel M, D\u00f6rken B, Daniel PT (2005) In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 5:105. https:\/\/doi.org\/10.1186\/1471-2407-5-105","journal-title":"BMC Cancer"},{"key":"5794_CR50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cancergencyto.2007.07.013","volume":"179","author":"O Lahiri","year":"2007","unstructured":"Lahiri O, Harris S, Packham G, Howell M (2007) p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genet Cytogenet 179:36\u201344. https:\/\/doi.org\/10.1016\/j.cancergencyto.2007.07.013","journal-title":"Cancer Genet Cytogenet"},{"key":"5794_CR51","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3324\/haematol.2013.101170","volume":"99","author":"A Benner","year":"2014","unstructured":"Benner A, Mansouri L, Rossi D et al (2014) MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica 99:1285\u20131291. https:\/\/doi.org\/10.3324\/haematol.2013.101170","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05794-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:06:10Z","timestamp":1735866370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5794"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05794-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the National Academy of Medicine from Buenos Aires, Argentina (N\u00ba 32\/23\/CEIANM). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}